Cipla slashes Indian price of generic Nexavar
This article was originally published in Scrip
Executive Summary
Less than a month after India approved its first-ever compulsory licence in the area of medicines for Bayer's anticancer Nexavar (sorafenib tosylate), the domestic firm Cipla has slashed the price of its generic version of the drug by more than 75%.